Ultragenyx Pharmaceutical Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RARE Nasdaq 2836 www.ultragenyx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) - Apr 2nd, 2026 6:30 am
Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study - Apr 1st, 2026 3:35 am
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - Mar 31st, 2026 10:15 am
Patient-Funded UX016 IND Clearance Might Change The Case For Investing In Ultragenyx Pharmaceutical (RARE) - Mar 31st, 2026 4:06 am
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy - Mar 30th, 2026 6:30 am
Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls - Mar 24th, 2026 7:36 am
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Alaska Airlines, ConocoPhillips, Commvault Systems, CoreWeave, Diamondback Energy, JFrog Ltd, Microsoft, and More - Mar 24th, 2026 5:54 am
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Mar 20th, 2026 2:30 pm
A Look At Ultragenyx Pharmaceutical’s Valuation After Recent Share Price Weakness - Mar 20th, 2026 1:06 pm
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights - Mar 19th, 2026 6:30 am
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - Mar 13th, 2026 6:23 am
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure - Mar 13th, 2026 4:17 am
Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency - Mar 12th, 2026 6:30 am
Ultragenyx Pharmaceutical (RARE) Valuation Check After Recent Share Price Volatility - Feb 27th, 2026 4:13 am
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory - Feb 24th, 2026 8:19 am
Ultragenyx to Participate at Investor Conferences in March - Feb 23rd, 2026 2:30 pm
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) - Feb 23rd, 2026 6:30 am
Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE) - Feb 16th, 2026 10:57 am
Ultragenyx Gene Therapy Progress And Restructuring Meet Deeply Discounted Valuation - Feb 15th, 2026 12:07 pm
Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A - Feb 13th, 2026 11:29 pm